What is the ticker symbol for Terns Pharmaceuticals?

Terns Pharmaceuticals trades under the ticker TERN on NASDAQ.

What sector does Terns Pharmaceuticals operate in?

Terns Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TERN in a portfolio?

PortView shows TERN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Terns Pharmaceuticals (TERN) Stock Analysis

NASDAQHealthcareBiotechnology

$52.95-0.03%

1-year price historyRange $2.78 – $53.17

52-week range$52.95

$2.66$53.19

What Terns Pharmaceuticals does

Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.

Key metrics

Market cap

$4.77B

P/E (TTM)

-51.41

EPS (TTM)

$-1.03

Beta

-0.38

Dividend yield

0.00%

Revenue / share

$0.00

50-day avg

$50.15

200-day avg

$29.48

52-week high

$53.19

52-week low

$2.66

CEO

Amy L. Burroughs

ETFs linked to TERN

Broad-market and Healthcare sector ETFs an investor holding Terns Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how TERN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze TERN in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Terns Pharmaceuticals?: Terns Pharmaceuticals trades under the ticker TERN on NASDAQ.
Which exchange is TERN listed on?: TERN is listed on NASDAQ.
What sector does Terns Pharmaceuticals operate in?: Terns Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze TERN in a portfolio?: PortView shows TERN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.